DBVT News and Press, DBV Technologies S.A. From 04/02/21

Montrouge, France, April 2, 2021 DBV Technologies Announces Appointment of Timothy E. Morris to Board of Directors DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, announced today the provi...

Monthly information regarding the total number of voting rights and total number of shares of the Company as of March 31, 2021 (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers ) Market : NYSE Euronext Paris ISIN Code:...

Montrouge, France, March 26, 2021 DBV Technologies Announces a New Chair of its Audit Committee and Date of its Annual General Meeting DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, ann...

Montrouge, France, March 17, 2021 DBV Technologies Announces Filing of 2020 Annual Report on Form 10-K and 2020 Universal Registration Document The Company also announces that it will enter the SBF 120 Index on Euronext DBV Technologies (Euronext: DBV – ISIN: FR00...

Monthly information regarding the total number of voting rights and total number of shares of the Company as of February 28, 2021 (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers ) Market : NYSE Euronext Paris ISIN ...

Shares of DBV Technologies (NASDAQ: DBVT) were trading higher on Friday following the company's release of its full-year 2020 earnings report. Much more important than its financial results, however, the company provided encouraging regulatory updates. As of 3:27 p.m. EST today, the...

DBV Technologies S.A. (DBVT) Q4 2020 Earnings Conference Call March 11, 2021 5:00 PM ET Company Participants Anne Pollak - Head of Investor Relations Daniel Tassé - Chief Executive Officer & Director Pascal Wotling - Chief Technical Operations Officer Pharis Mohideen - Chief Medical ...

DBV Technologies (DBVT): FY GAAP EPS of -$2.95 beats by $0.75.Revenue of $11.28M (-23.3% Y/Y) misses by $6.49M.Press Release For further details see: DBV Technologies EPS beats by $0.75, misses on revenue

Montrouge, France, March 11, 2021 DBV Technologies Reports Full-Year 2020 Financial Results and Recent Business Developments DBV Technologies S.A. (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today re...

Montrouge, France, March 5, 2021 DBV Technologies to Participate in the H.C. Wainwright Global Life Sciences Conference DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced th...